indication

For the treatment of angina pectoris and hypertension.

pharmacology

Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension.

mechanism of action

Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors. By binding and antagonizing beta-1 receptors Bevantolol inhibits the normal normal epinephrine-mediated sympathetic actions such as increased heart rate. This has the effect of decreasing preload and blood pressure.

drug interactions

Chlorpropamide: The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.

Clonidine: Increased hypertension when clonidine stopped

Dihydroergotamine: Ischemia with risk of gangrene

Disopyramide: The beta-blocker, bevantolol, may increase the toxicity of disopyramide.

Epinephrine: Hypertension, then bradycardia

Ergotamine: Ischemia with risk of gangrene

Fenoterol: Antagonism

Formoterol: Antagonism

Gliclazide: The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.

Glyburide: The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.

Ibuprofen: Risk of inhibition of renal prostaglandins

Indomethacin: Risk of inhibition of renal prostaglandins

Insulin Glargine: The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.

Methysergide: Ischemia with risk of gangrene

Orciprenaline: Antagonism

Pipobroman: Antagonism

Piroxicam: Risk of inhibition of renal prostaglandins

Prazosin: Risk of hypotension at the beginning of therapy

Repaglinide: The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia.

Terbutaline: Antagonism